Aurisco Pharmaceutical Co Ltd (605116) — Capital Reinvestment Ratio
Aurisco Pharmaceutical Co Ltd (605116) has a Capital Reinvestment Ratio of 1.63x as of December 2024, meaning it reinvests 2% of its operating cash flow (CN¥332.41 Million) in capital expenditures (CN¥540.28 Million). See Aurisco Pharmaceutical Co Ltd (605116) balance sheet quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Aurisco Pharmaceutical Co Ltd Capital Reinvestment Ratio (2017–2024)
This chart tracks Aurisco Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 8 annual periods. Check Aurisco Pharmaceutical Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Aurisco Pharmaceutical Co Ltd (2017–2024)
Year-by-year Capital Reinvestment Ratio for Aurisco Pharmaceutical Co Ltd from 2017 to 2024. For live market cap and broader valuation context, see market cap of Aurisco Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.63x | CN¥332.41 Million | CN¥540.28 Million | ▲ +105.2% |
| 2023 | 0.79x | CN¥385.61 Million | CN¥305.48 Million | ▼ -39.0% |
| 2022 | 1.30x | CN¥166.41 Million | CN¥216.23 Million | ▲ +4.5% |
| 2021 | 1.24x | CN¥201.57 Million | CN¥250.61 Million | ▲ +67.9% |
| 2020 | 0.74x | CN¥214.48 Million | CN¥158.80 Million | ▲ +83.8% |
| 2019 | 0.40x | CN¥179.90 Million | CN¥72.47 Million | ▼ -53.0% |
| 2018 | 0.86x | CN¥109.77 Million | CN¥94.14 Million | ▼ -5.1% |
| 2017 | 0.90x | CN¥117.91 Million | CN¥106.60 Million | — |